Day: October 20, 2025

40% increase in cultivation capacity expected to drive revenue and EBITDA growth in Rubicon’s premium cannabis products  The Company also announces the naming of cultivation facilities to Pacifica (previously “Delta Facility”) and Cascadia (previously “Hope Facility”).VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics”, “Rubicon”, or the “Company”), Canada’s leading premium licensed producer focused on cultivating and selling organic certified, premium and super-premium cannabis products, today announced the Cascadia facility, located in Hope, British Columbia, has received its license to cultivate, process, and store cannabis from Health Canada. The license will enable Rubicon to begin cultivating cannabis at the 47,500 square foot, purpose-built...

Strategic move positions Company for sustained listing compliance and better alignment with business profile SAN JOSE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) — zSpace, Inc. (NASDAQ: ZSPC), a global leader in immersive augmented reality (AR) learning solutions for education, today announced that it has received approval from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its common stock from the Nasdaq Global Market to the Nasdaq Capital Market. This transfer was effective as of the opening of trading on October 16, 2025. This announcement has no immediate effect on the listing or trading of the Company’s common stock. The Company’s shares will continue to trade under the “ZSPC” ticker symbol. In connection with the transfer, Nasdaq confirmed...

Watch the Video at www.VoteWKHS.com CINCINNATI, Oct. 20, 2025 (GLOBE NEWSWIRE) — Workhorse Group, Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company focused on pioneering the transition to zero-emission commercial vehicles, today posted a video at www.VoteWKHS.com from Workhorse CEO Rick Dauch and Motiv CEO Scott Griffith. The video outlines the compelling benefits of the Company’s transaction with Motiv and the reasons why Workhorse shareholders should vote FOR all proposals in connection with Workhorse’s upcoming 2025 Annual General Meeting of Shareholders (the “Annual Meeting”) on November 12, 2025. Watch the video here: www.VoteWKHS.com VOTE TODAY Shareholders of record as of the close of business on September 18, 2025, are eligible to vote on the proposals before and at the meeting. Shareholders...

Certara celebrates its 200 published papers and 11 scientists on Stanford/Elsevier top 2% cited researchers list in 2025 RADNOR, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its continued influence in pharmaceutical research. With more than 200 papers authored by Certara scientists* this past year and 11 Certara scientists included on the 2025 update of Stanford/Elsevier’s ranking of the top 2% most cited scientists across the globe, Certara’s powerhouse of scientific knowledge continues to drive innovation in drug discovery and development. Certara’s highly ranked experts reflect the company’s commitment to scientific insight and developing technological solutions that further patients’ access to new medicines. Now in its 8th iteration,...

WESTBROOK, Maine, Oct. 20, 2025 (GLOBE NEWSWIRE) — Synergy CHC Corp. (NASDAQ: SNYR), a leading consumer health and wellness company, today announced a strategic distribution partnership with Atlantic Importing Company, one of Southern New England’s top multi-category distributors. The agreement will expand retail availability of FOCUSfactor® Focus + Energy functional beverages and brain-health energy shots across Massachusetts, Connecticut, and Rhode Island, marking a significant milestone in Synergy’s mission to make clean energy, mental clarity, and cognitive performance products accessible to consumers throughout the Northeast. By combining Atlantic Importing’s robust retail network with Synergy’s growing lineup of science-backed functional beverages, the partnership positions FOCUSfactor® as a front-runner in the fast-growing...

CARMEL, Ind., Oct. 20, 2025 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at and participate in the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference Date: Monday, November 10, 2025Format: Fireside chat and 1×1 meetingsTime: 3:30 p.m. – 3:55 p.m. ETLocation: Boston, MA Stifel Healthcare Conference Date: Wednesday, November 12, 2025Format: Fireside chat and 1×1 meetingsTime: 3:20 p.m. – 3:50 p.m. ETLocation: New York, NY Jefferies Global Healthcare Conference...

New embedded payment service will deliver seamless merchant experience, advanced BNPL options, and a unified balance dashboard, launching for US merchants in 2026 AUSTIN, Texas, Oct. 20, 2025 (GLOBE NEWSWIRE) — Commerce, (Nasdaq: CMRC), an open, intelligent ecosystem of technology solutions and the parent company of BigCommerce, today announced a new embedded payment processing solution available exclusively to BigCommerce merchants. Powered by PayPal (Nasdaq: PYPL), BigCommerce Payments is slated for a U.S. launch in 2026, with international expansion planned in subsequent phases. This strategic expansion builds on more than a decade of close partnership between Commerce and PayPal, marking a new chapter in their collaboration. Through this optional co-branded integration, merchants will gain access to advanced payment capabilities,...

Adverse events (AEs) generally transient and readily manageable; only 2 cases of cytokine release syndrome (CRS) Prolonged tumor control with increasing doses of BA3182; confirmed partial response (cPR) at 0.6 mg in a patient with intrahepatic cholangiocarcinoma without progression for >6 months​ Maximally tolerated dose not yet defined; dose escalation continues; currently testing 1.8 mg dose level​SAN DIEGO, Oct. 20, 2025 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preliminary clinical data from a Phase 1 study of BA3182 during a poster presentation titled “Preliminary Results from a First-in-Human Phase 1 Study of BA3182, a Dual-Conditionally...